Abstract
Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD, reviewed the potential role of PARP inhibition in various malignancies, how to select patients who are appropriate candidates, and guidance on devising treatment plans that include PARP inhibitors for patients with ovarian or breast cancer based on genetic profiles, tolerability, dosing schedules, and other key factors.
